Literature DB >> 20424458

Naltrexone implants compared to methadone: outcomes six months after prison release.

Philipp P Lobmaier1, Nikolaj Kunøe, Michael Gossop, Tormod Katevoll, Helge Waal.   

Abstract

BACKGROUND: After prison release, offenders with heroin use problems are at high risk of relapse and overdose death. There is a particular need for treatments that can be initiated in prison and continued after release into the community. Methadone maintenance treatment has been shown to reduce heroin use, criminality and mortality. Naltrexone implant treatment has not previously been evaluated in prison settings.
METHODS: This study compares the effects of naltrexone implants and methadone treatment on heroin and other illicit drug use, and criminality among heroin-dependent inmates after release from prison.
RESULTS: Forty-six volunteers were randomly allocated to naltrexone implants or methadone before release. Intention-to-treat analyses showed reductions in both groups in frequency of use of heroin and benzodiazepines, as well as criminality, 6 months after prison release.
CONCLUSIONS: Naltrexone implants may be a valuable treatment option in prison settings. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424458     DOI: 10.1159/000313336

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  19 in total

1.  A randomized trial of methadone initiation prior to release from incarceration.

Authors:  Michelle McKenzie; Nickolas Zaller; Samuel L Dickman; Traci C Green; Amisha Parihk; Peter D Friedmann; Josiah D Rich
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

2.  Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder.

Authors:  An-Li Wang; Steven B Lowen; Igor Elman; Zhenhao Shi; Victoria P Fairchild; Alexander Bouril; Ruben C Gur; Daniel D Langleben
Journal:  J Subst Abuse Treat       Date:  2017-10-18

3.  Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS.

Authors:  Maxim Polonsky; Lyuba Azbel; Jeffrey A Wickersham; Faye S Taxman; Evgeny Grishaev; Sergey Dvoryak; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2014-12-22       Impact factor: 4.492

4.  Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators.

Authors:  Maxim Polonsky; Julia Rozanova; Lyuba Azbel; Chethan Bachireddy; Jacob Izenberg; Tetiana Kiriazova; Sergii Dvoryak; Frederick L Altice
Journal:  AIDS Behav       Date:  2016-12

5.  Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence.

Authors:  Daniel D Langleben; Elliot L Busch; Charles P O'Brien; Igor Elman
Journal:  Psychopharmacology (Berl)       Date:  2011-09-30       Impact factor: 4.530

6.  Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.

Authors:  Kelly E Moore; Walter Roberts; Holly H Reid; Kathryn M Z Smith; Lindsay M S Oberleitner; Sherry A McKee
Journal:  J Subst Abuse Treat       Date:  2018-12-15

7.  Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system.

Authors:  Karen L Cropsey; Peter S Lane; Galen J Hale; Dorothy O Jackson; C Brendan Clark; Karen S Ingersoll; M Aminul Islam; Maxine L Stitzer
Journal:  Drug Alcohol Depend       Date:  2011-07-23       Impact factor: 4.492

8.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

Review 9.  Mental health of prisoners: prevalence, adverse outcomes, and interventions.

Authors:  Seena Fazel; Adrian J Hayes; Katrina Bartellas; Massimo Clerici; Robert Trestman
Journal:  Lancet Psychiatry       Date:  2016-07-14       Impact factor: 27.083

Review 10.  Improving clinical outcomes for naltrexone as a management of problem alcohol use.

Authors:  Gary K Hulse
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.